BioSpace News Archive

OmniTier announced that its CompStor® family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.

Valo Health, LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, announced today that its CEO and founder, David Berry, will present at the following investor conferences in March:

Children’s National Hospital and Takeda Pharmaceutical Company Limited announced the creation of the Rare Disease Clinical Activity Protocols program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.

Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, introduces the KidneyCare:365 program focused on providing care coordination to people living with chronic kidney disease (CKD) working in close partnership with their physicians and physician networks including InterWell Health.

Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changing drugs, today announced the appointment of Nish Lathia as Chief Product Officer (CPO), a newly established executive leadership position at the company.

Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the closing, on February 26, 2021, of its previously announced underwritten public offering of 1,971,100 shares of its common stock,

LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa).

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference

CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) cannot approve the New Drug Application (NDA) for DefenCath™ (taurolidine/heparin catheter lock solution) in its present form

DNA Script, a leading pioneer in enabling DNA on demand, shared data at this year’s Advances in Genome Biology and Technology (AGBT) General Meeting that demonstrate the comparable performance of the company’s enzymatically synthesized oligos to traditional chemically synthesized DNA in their quest to reliably support genomics and life science applications.